Duration of anti-tubercular treatment in tuberculous meningitis: challenges and opportunity

Neurol India. 2010 Sep-Oct;58(5):723-6. doi: 10.4103/0028-3886.72182.

Abstract

Background: The duration of anti-tuberculous therapy in tuberculous meningitis is controversial. There is variation in recommendations by different societies and expert groups on this issue.

Objective: To determine the strength of evidence for short-term therapy in tuberculous meningitis through review of literature and critical appraisal.

Materials and methods: Cochrane CENTRAL (Issue 4, 2010), TRIP database, and PubMed (from 1966 to present) were searched for relevant papers with keywords 'meningeal tuberculosis' and tuberculous meningitis' combined with 'chemotherapy'. A critical appraisal of a systematic review was done using standard criteria.

Results: A total of 10 relevant papers were identified. All papers were included in a systematic review. The systematic review did not specify study design of studies to be included, had only case series but no randomised controlled trial, and unclear definition of endpoints.

Conclusions: The evidence base for short-term therapy for tuberculous meningitis is weak. There is a need to conduct a randomised controlled trial with non-inferiority hypothesis of adequate sample size with well-defined end points and adequate follow-up. This is a challenge as well as opportunity for Indian neurologists.

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Databases, Factual / statistics & numerical data
  • Humans
  • Time Factors
  • Tuberculosis, Meningeal / cerebrospinal fluid
  • Tuberculosis, Meningeal / diagnosis
  • Tuberculosis, Meningeal / drug therapy*
  • Tuberculosis, Meningeal / epidemiology

Substances

  • Antitubercular Agents